See more : SHANTI GURU INDUSTRIES LIMITED (SHANTIGURU.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Monte Rosa Therapeutics, Inc. (GLUE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Monte Rosa Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- KKO International SA (ALKKO.PA) Income Statement Analysis – Financial Results
- Nestlé S.A. (NSRGF) Income Statement Analysis – Financial Results
- LithiumBank Resources Corp. (LBNKF) Income Statement Analysis – Financial Results
- Guyana Goldstrike Inc. (GYNAF) Income Statement Analysis – Financial Results
- ITI (7716.TWO) Income Statement Analysis – Financial Results
Monte Rosa Therapeutics, Inc. (GLUE)
About Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 6.22M | 8.56M | 2.13M | 537.00K | 72.00K |
| Gross Profit | -6.22M | -8.56M | -2.13M | -537.00K | -72.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 105.05M | 85.06M | 57.16M | 24.01M | 7.35M |
| General & Administrative | 32.04M | 27.32M | 15.73M | 4.01M | 644.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 32.04M | 27.32M | 15.73M | 4.01M | 644.00K |
| Other Expenses | 0.00 | 0.00 | -960.00K | -7.68M | 276.00K |
| Operating Expenses | 143.31M | 112.38M | 72.88M | 28.01M | 7.99M |
| Cost & Expenses | 143.31M | 112.38M | 72.88M | 28.01M | 7.99M |
| Interest Income | 9.33M | 3.76M | 46.00K | 9.00K | 12.00 |
| Interest Expense | 0.00 | 3.76M | 0.00 | 0.00 | 1.00K |
| Depreciation & Amortization | 6.22M | 8.56M | 2.13M | 537.00K | 72.00K |
| EBITDA | -137.09M | -99.94M | -70.75M | -27.47M | -7.67M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -143.31M | -112.38M | -72.88M | -28.01M | -7.99M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 8.30M | 3.88M | -1.08M | -7.87M | 254.00K |
| Income Before Tax | -135.01M | -108.50M | -73.96M | -35.88M | -7.74M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 338.00K | -3.88M | -2.02M | 189.00K | 277.00K |
| Net Income | -135.35M | -104.62M | -71.94M | -36.07M | -8.02M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.63 | -2.22 | -1.55 | -0.82 | -0.18 |
| EPS Diluted | -2.63 | -2.22 | -1.55 | -0.82 | -0.18 |
| Weighted Avg Shares Out | 51.40M | 47.23M | 46.54M | 44.00M | 44.00M |
| Weighted Avg Shares Out (Dil) | 51.40M | 47.23M | 46.54M | 44.00M | 44.00M |
Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024
Phase 1/2 clinical trial of MRT-2359 in MYC-driven solid tumors on track; recommended Phase 2 dose (RP2D) expected in Q2 2024 Received US FDA Fast Track Designation for MRT-2359 for previously treated, metastatic small cell lung cancer with L- or...
Monte Rosa Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
BOSTON, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus Warmuth, M.D.
Monte Rosa Therapeutics to Present at Piper Sandler Healthcare Conference
BOSTON, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will participate in a fireside discussion at the 35th Annual Piper Sandler Healthcare Conference in...
Monte Rosa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
Interim data from Phase 1/2 clinical trial of MRT-2359 demonstrated tumor reductions in patients with biomarker-positive cancers; recommended Phase 2 dose expected in Q2 2024 Announced strategic collaboration with Roche to discover novel molecular glue degraders targeting cancer and neurological...
Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2023 Demonstrating Potential of MRT-6160, a VAV1-targeted Molecular Glue Degrader, to Treat Immunological and Inflammatory Diseases
Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2023 Demonstrating Potential of MRT-6160, a VAV1-targeted Molecular Glue Degrader, to
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
BOSTON, Oct. 27, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will participate in the following investor conferences: TD Cowen 7th Annual Fall Oncology Innovation Summit...
Monte Rosa Therapeutics Announces $25 Million Registered Direct Offering, Priced At- the-Market Under Nasdaq Rules
BOSTON, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that it has raised $25 million at-the-market from a life sciences-dedicated investor. The company...
Down -56.34% in 4 Weeks, Here's Why You Should You Buy the Dip in Monte Rosa Therapeutics (GLUE)
Monte Rosa Therapeutics (GLUE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal...
Monte Rosa Therapeutics Announces Strategic Collaboration with Roche to Discover Novel Molecular Glue Degraders Targeting Cancer and Neurological Diseases
Monte Rosa Therapeutics Announces Strategic Collaboration with Roche to Discover Novel Molecular Glue Degraders Targeting Cancer and Neurological Diseases
Monte Rosa Therapeutics Announces Interim PK/PD and Clinical Data for MRT-2359 in Phase 1/2 Trial for MYC-Driven Solid Tumors
Optimal levels of degradation of GSPT1 in peripheral blood mononuclear cells and tumors observed at all doses, consistent with preclinical studies Tumor size reductions observed in patients with biomarker-positive tumors Safety profile supports further clinical development of MRT-2359 Conference call...
Source: https://incomestatements.info
Category: Stock Reports